终末期实践评分的推导与表现:用于解读全球重症患者治疗限制决策
研究基于Ethicus-1(1999-2000年)与Ethicus-2(2015-2016年)两期前瞻性观察比较研究(22个欧洲ICU,4952例患者)推导加权终末期实践评分,并在全球Ethicus-2单期前瞻性观察研究(199个ICU、8个世界区域、12200例患者)中验证。比较研究GEE分析显示,每周会议中讨论终末期议题(OR 0.55,95%CI 0.30–0.99)、终末期指南(OR 0.52,95%CI 0.31–0.87)、终末期方案(OR 15.08,95%CI 3.88–58.59)、姑息治疗会诊(OR 2.63,95%CI 1.23–5.60)及终末期立法(OR 3.24,95%CI 1.60–6.55)与限制决策显著相关(均P<0.05)。全球验证中,加权评分与限制决策显著相关(OR 1.12,95%CI 1.03–1.22;P=0.008)。评分最重要的组分为ICU终末期方案、姑息治疗会诊和国家终末期立法。
要点
- 比较研究GEE显示,ICU终末期方案与限制决策强相关(OR 15.08,95%CI 3.88–58.59),为评分最重要组分之一。
- 姑息治疗会诊(OR 2.63,95%CI 1.23–5.60)和国家终末期立法(OR 3.24,95%CI 1.60–6.55)同样与限制决策显著相关。
- 每周会议中讨论终末期议题(OR 0.55,95%CI 0.30–0.99)和终末期指南(OR 0.52,95%CI 0.31–0.87)与限制决策呈负相关。
- 全球199个ICU验证中,加权终末期实践评分与限制决策显著相关(OR 1.12,95%CI 1.03–1.22;P=0.008),部分解释全球差异。
适用人群与场景
- 比较研究:22个欧洲ICU的4952例患者,评估1999-2000年(Ethicus-1)与2015-2016年(Ethicus-2)限制决策频率。
- 全球研究:199个ICU(8个世界区域)的12200例患者,单期前瞻性观察评估限制决策频率。
研究设计与关键结果
- 研究类型:两期前瞻性观察比较研究(Ethicus-1 vs Ethicus-2)及全球单期前瞻性观察研究(Ethicus-2)。
- 比较研究GEE分析(22/22 ICU,n=4592):每周会议中讨论终末期议题OR 0.55(95%CI 0.30–0.99)、终末期指南OR 0.52(95%CI 0.31–0.87)、终末期方案OR 15.08(95%CI 3.88–58.59)、姑息治疗会诊OR 2.63(95%CI 1.23–5.60)、终末期立法OR 3.24(95%CI 1.60–6.55),均与限制决策显著相关(均P<0.05)。
- 全球研究GEE分析(186/199 ICU,n=11574):加权终末期实践评分与限制决策显著相关(OR 1.12,95%CI 1.03–1.22;P=0.008)。
- 评分最重要组分:ICU终末期方案、姑息治疗会诊、国家终末期立法。
证据类型、等级与局限
- 证据类型:前瞻性观察研究(两期比较研究及全球单期研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Limitations of life-sustaining interventions in intensive care units (ICUs) exhibit substantial changes over time, and large, contemporary variation across world regions. We sought to determine whether a weighted end-of-life practice score can explain a large, contemporary, worldwide variation in limitation decisions.
METHODS: The 2015-2016 (Ethicus-2) vs. 1999-2000 (Ethicus-1) comparison study was a two-period, prospective observational study assessing the frequency of limitation decisions in 4952 patients from 22 European ICUs. The worldwide Ethicus-2 study was a single-period prospective observational study assessing the frequency of limitation decisions in 12,200 patients from 199 ICUs situated in 8 world regions. Binary end-of-life practice variable data (1 = presence; 0 = absence) were collected post hoc (comparison study, 22/22 ICUs, n = 4592; worldwide study, 186/199 ICUs, n = 11,574) for family meetings, daily deliberation for appropriate level of care, end-of-life discussions during weekly meetings, written triggers for limitations, written ICU end-of-life guidelines and protocols, palliative care and ethics consultations, ICU-staff taking communication or bioethics courses, and national end-of-life guidelines and legislation. Regarding the comparison study, generalized estimating equations (GEE) analysis was used to determine associations between the 12 end-of-life practice variables and treatment limitations. The weighted end-of-life practice score was then calculated using GEE-derived coefficients of the end-of-life practice variables. Subsequently, the weighted end-of-life practice score was validated in GEE analysis using the worldwide study dataset.
RESULTS: In comparison study GEE analyses, end-of-life discussions during weekly meetings [odds ratio (OR) 0.55, 95% confidence interval (CI) 0.30-0.99], end-of-life guidelines [OR 0.52, (0.31-0.87)] and protocols [OR 15.08, (3.88-58.59)], palliative care consultations [OR 2.63, (1.23-5.60)] and end-of-life legislation [OR 3.24, 1.60-6.55)] were significantly associated with limitation decisions (all P < 0.05). In worldwide GEE analyses, the weighted end-of-life practice score was significantly associated with limitation decisions [OR 1.12 (1.03-1.22); P = 0.008].
CONCLUSIONS: Comparison study-derived, weighted end-of-life practice score partly explained the worldwide study's variation in treatment limitations. The most important components of the weighted end-of-life practice score were ICU end-of-life protocols, palliative care consultations, and country end-of-life legislation.
参考来源
- Mentzelopoulos SD, Chen S, Nates JL, et al. Derivation and performance of an end-of-life practice score aimed at interpreting worldwide treatment-limiting decisions in the critically ill. Crit Care. 2022. PMID: 35418103. doi:10.1186/s13054-022-03971-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。